Testing ADC Drug Effectiveness Using Lung Cancer Lab Models
Part of Cancer, Lungs & breathing clinical trials.
This research study tests how a lung cancer drug called Trastuzumab deruxtecan (T-DXd) works by growing your cancer cells in a lab dish and studying them with your immune cells. The goal is to better understand which patients might benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have non-small cell lung cancer (NSCLC), not small cell lung cancer
- Be planning to receive or already receiving T-DXd treatment
- Have cancer cells that can be grown in the lab (organoids) with matching immune cells available
- Have cancer cells that show specific protein markers (HER2 and TROP2) on testing
- Sign a consent form and be willing to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This trial tests a drug called trastuzumab deruxtecan (an antibody-drug conjugate) in people with advanced non-small cell lung cancer that has high levels of HER2. The drug is designed to target and kill cancer cells while sparing healthy cells, and the study will see how well it works and how safe it is.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
Hear when a new HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.